A Philadelphia jury found that a subsidiary downplayed the risks that the anti-psychotic drug could lead to breast growth in boys.
Johnson & Johnson Hit With $8 Billion Jury Verdict in Risperdal Suit
The New York Times - 9 Oct 2019 03:47
A Philadelphia jury found that a subsidiary downplayed the risks that the anti-psychotic drug could lead to breast growth in boys.
Share this Article
Comment on this Article
Recommended
Please to comment